For almost 50 years, the NHS benefited from easy access to a large market, meaning it’s been first in the queue for the latest innovations. But what impact might Brexit have on medicines, medical devices and life sciences in the UK? Mark Dayan explains, in a blog that was first published in the BMJ on 26 February.